CartiHeal Announces Positive Interim Results of Agili-C IDE Study

CartiHeal, announced that per the results of an interim analysis of the Agili-C™ Investigational Device Exemption study, trial enrollment will stop at 250 subjects. Agili-C is a proprietary biocompatible implant for the treatment of cartilage lesions in arthritic and non-arthritic joints.

The clinical study is designed to evaluate Agili-C...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us